Measurable residual disease (MRD) testing

Adaptive is a commercial-stage biotechnology company and a proven leader in measurable residual disease (MRD) testing for lymphoid cancers. The company’s primary product is clonoSEQ®, which is trusted by patients, providers, and biopharma companies for both clinical care and research. Powered by next-generation sequencing, clonoSEQ detects and tracks cancer cells that can remain during and after treatment and that may cause disease recurrence. clonoSEQ is shaping modern lymphoid cancer care—enabling clinicians to individualize therapy, lessen treatment burden, and help patients reach their treatment goals.